Skip to main content
HUMA
NASDAQ Life Sciences

Humacyte 为其血管创伤治疗产品 Symvess 向以色列卫生部提交上市申请

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$1.14
Mkt Cap
$216.156M
52W Low
$0.88
52W High
$3.36
Market data snapshot near publication time

summarizeSummary

Humacyte，一家商业阶段生物技术公司，已向以色列卫生部提交了 Symvess 产品的上市许可申请（MAA），该产品是一种用于动脉创伤修复的无细胞组织工程血管。该提交标志着公司国际商业化战略的重要一步，Symvess 已获得 FDA 批准用于四肢血管创伤治疗。该公司还正在寻求一种机制，以便在获得完整 MAA 批准之前，使 Symvess 在以色列的医院中逐一提供，可能为公司提供早期收入来源。这种扩张进入以色列市场，并计划进一步扩张到中东地区，对于公司的增长前景和产品采用是一个积极的发展。

在该公告发布时，HUMA的交易价格为$1.14，交易所为NASDAQ，所属行业为Life Sciences，市值约为$2.2亿。 52周交易区间为$0.88至$3.36。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed HUMA - Latest Insights

HUMA
Apr 28, 2026, 4:52 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Humacyte Seeks Shareholder Approval to Increase Authorized Shares by 200 Million, Paving Way for Future Capital Raises
Sentiment: Neutral
View Wiseek Article
HUMA
Apr 24, 2026, 8:09 AM EDT
Filing Type: 8-K
Importance Score:
7
Humacyte Reclaims Global Commercial Rights for Symvess from Fresenius
Sentiment: Positive
View Wiseek Article
HUMA
Apr 21, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Israeli Ministry of Health Accepts Humacyte's Symvess MAA, Initiating 180-Day Review
Sentiment: Positive
View Wiseek Article
HUMA
Apr 17, 2026, 4:30 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Humacyte Seeks Shareholder Approval to Increase Authorized Shares by 200 Million, Paving Way for Significant Future Dilution
Sentiment: Negative
View Wiseek Article
HUMA
Mar 27, 2026, 4:45 PM EDT
Filing Type: 10-K
Importance Score:
9
Humacyte Issues Going Concern Warning Amidst Low Revenue and Dilutive Financing
Sentiment: Negative
View Wiseek Article
HUMA
Mar 27, 2026, 7:00 AM EDT
Source: Reuters
Importance Score:
8
Humacyte Reports Wider-Than-Expected Q4 Losses, Missing Operating and Net Income Estimates
Sentiment: Negative
View Wiseek Article
HUMA
Mar 19, 2026, 4:33 PM EDT
Filing Type: 8-K
Importance Score:
8
Humacyte Prices $20M Registered Direct Offering at Discount, Securing Capital for Operations
Sentiment: Negative
View Wiseek Article
HUMA
Mar 19, 2026, 4:26 PM EDT
Filing Type: 424B3
Importance Score:
9
Humacyte Finalizes $20M Offering at Deep Discount, Discloses Substantial Doubt About Going Concern
Sentiment: Negative
View Wiseek Article
HUMA
Mar 19, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
$20M Registered Direct Offering Priced by Humacyte, Signaling Share Dilution
Sentiment: Negative
View Wiseek Article
HUMA
Mar 19, 2026, 8:25 AM EDT
Filing Type: 8-K
Importance Score:
8
Humacyte Halts $60M ATM Offering, Secures Saudi Arabia Deal, and Files for Israeli Approval
Sentiment: Positive
View Wiseek Article